Nattokinase

Bacillus subtilis var. natto (producing organism)
Evidence Level
Limited
11 Clinical Trials
3 Documented Benefits
2/5 Evidence Score

Nattokinase is an enzyme (subtilisin NAT) made by Bacillus subtilis var. natto, the bacterium used to ferment soybeans into the Japanese food natto. Supplements are standardized in fibrinolytic units (FU), and most trials used 2,000 FU a day. In lab tests it breaks down fibrin, the protein mesh of a blood clot, and inactivates PAI-1, a natural brake on clot breakdown. Two 8-week placebo-controlled trials in adults with raised blood pressure reported lower readings with nattokinase, and both had ties to the enzyme's maker. A larger 3-year placebo-controlled trial in 265 healthy older adults found no effect on carotid artery wall thickening, arterial stiffness, blood pressure or any laboratory measure. Nattokinase lengthened clotting test times compared with placebo, so it is not for people on blood thinners or with clotting disorders, and it can trigger allergy in people sensitized to natto.

Studied Dose Placebo-controlled trials used 2,000 FU capsules for 8 weeks, 100 mg of NSK-SD a day (standardized to at least 2,000 FU) for 8 weeks, 100 mg of nattokinase a day for 8 weeks, 2,000 FU a day for about 3 years and 8,000 FU a day for 6 months; an open-label study used 4,000 FU a day for 2 months.
Active Compound Nattokinase (subtilisin NAT), a serine protease from Bacillus subtilis var. natto

Benefits

Blood Pressure in Placebo-Controlled Trials

In an 8-week placebo-controlled trial of 86 adults with untreated systolic pressure of 130 to 159 mmHg (73 finished), 2,000 FU capsules lowered pressure by a net 5.55/2.84 mmHg. A second 8-week trial of 100 mg a day lowered diastolic pressure. Both had maker ties. A 3-year trial in 265 healthy older adults found no effect on blood pressure.

Fibrin Breakdown Activity

In lab work the enzyme dissolves fibrin, the protein mesh of a blood clot, and inactivates PAI-1, a natural brake on clot breakdown. In a placebo-controlled crossover in 12 healthy young men, one 2,000 FU dose raised D-dimer and fibrin breakdown products and lengthened aPTT, with all values staying in the normal range.

Clotting Factors and Clotting Times

In an open-label study without a placebo group, fibrinogen and clotting factors VII and VIII fell by 7% to 19% over 2 months in 45 adults taking 4,000 FU a day, with blood lipids unchanged. An 8-week placebo-controlled trial lengthened platelet closure time and aPTT. The 3-year trial found no change in clotting or other lab measures.

Mechanism of action

1

Direct Fibrin Breakdown

Nattokinase (subtilisin NAT) is a serine protease. In laboratory clot experiments it dissolved fibrin directly and boosted clot breakdown driven by tissue plasminogen activator (tPA), the body's own clot-dissolving signal. These are test-tube findings.

2

PAI-1 Cleavage

In the same laboratory work, nattokinase cut plasminogen activator inhibitor 1 (PAI-1), a natural inhibitor of clot breakdown, at its active site and inactivated it, so clots rich in PAI-1 broke down faster. This has not been shown directly after oral doses in people.

3

ACE-Inhibiting Peptide Fragments

In the test tube, nattokinase inhibited angiotensin I converting enzyme (ACE), and heat-treated nattokinase released small peptides such as LY and FY that inhibited it more. The authors suggest this may relate to blood pressure effects of eating natto; it has not been measured in people.

Clinical trials

1
Nattokinase and Blood Pressure Over 8 Weeks (Korea)
PubMed

Randomized, double-blind, placebo-controlled trial of nattokinase 2,000 FU capsules or placebo for 8 weeks; 86 randomized and 73 completed. Two co-authors were from Japan Bio Science Laboratory, a nattokinase maker (Kim et al. 2008, Hypertens Res)

86 adults aged 20 to 80 with untreated systolic blood pressure of 130 to 159 mmHg (pre-hypertension or stage 1 hypertension).

Net change versus placebo: systolic -5.55 mmHg (95% CI -10.5 to -0.57) and diastolic -2.84 mmHg (95% CI -5.33 to -0.33), both p<0.05; plasma renin activity fell by a net 1.17 ng/mL/h.

2
NSK-SD Nattokinase and Blood Pressure Over 8 Weeks (North America)
PubMed

Randomized, double-blind, placebo-controlled trial at two sites, registered as NCT02886507 with blood pressure as the primary outcome; 100 mg of NSK-SD a day or placebo for 8 weeks; 79 enrolled and 74 completed. Sponsored by JBSL-USA, the distributor of the product tested (Jensen et al. 2016, Integr Blood Press Control)

79 adults with systolic blood pressure of 130 mmHg or more or diastolic of 90 mmHg or more.

Diastolic pressure fell from 87 to 84 mmHg on nattokinase and stayed at 87 mmHg on placebo (P<0.05 between groups); in men it fell from 86 to 81 mmHg (P<0.006). Systolic pressure also fell, more in men; von Willebrand factor fell in women only at P<0.1.

3
Nattokinase Over a Median of 3 Years (NAPS)
PubMed

Randomized, double-blind, placebo-controlled trial (NCT02080520, University of Southern California) of nattokinase 2,000 FU a day or placebo in people without clinical evidence of cardiovascular disease. Primary outcomes were the yearly change in carotid intima-media thickness and carotid stiffness; additional outcomes were clinical parameters including blood pressure and laboratory measures (metabolic, clotting, fibrinolysis and inflammatory), with no significant effect on blood pressure or any laboratory measure. Funder not stated in the abstract (Hodis et al. 2021, Clin Hemorheol Microcirc)

265 healthy adults at low risk, median age 65.3 years.

No significant difference from placebo in the yearly change in carotid wall thickness or stiffness (primary outcomes), and no significant effect on any laboratory measure or on the other clinical measures listed in the study details.

4
Clotting Times Over 8 Weeks (Korea)
PubMed

Randomized, placebo-controlled trial (NCT02913170, Yonsei University) for 8 weeks in people with borderline to moderately high serum cholesterol (200 to 280 mg/dL); 100 mg of nattokinase a day per the registry. A published correction (PMID 31287455) added co-author Inoue K of Japan Bio Science Laboratory, a nattokinase maker (Yoo et al. 2019, Food Funct)

100 adults without diabetes, 50 per group.

Collagen-epinephrine closure time (a platelet function test) and activated partial thromboplastin time (aPTT) rose more on nattokinase than on placebo (P = 0.001 and P = 0.016); prothrombin time also rose within the nattokinase group.

5
Single 2,000 FU Dose and Clotting Tests (Crossover)
PubMed

Randomized, double-blind, placebo-controlled crossover; one 2,000 FU dose of NSK-SD (Japan Bio Science Laboratory) or placebo, with blood drawn over 8 hours; funded by a Japanese government research grant (KAKENHI) (Kurosawa et al. 2015, Sci Rep)

12 healthy young men.

After nattokinase, D-dimer rose at 6 and 8 hours, fibrin/fibrinogen degradation products rose at 4 hours, factor VIII activity fell and aPTT lengthened (all p<0.05 or lower); all values stayed within the normal range.

6
Clotting Factors Over 2 Months (Taiwan, Open-Label)
PubMed

Open-label, self-controlled study with no placebo group (NCT00447434, Changhua Christian Hospital); two 2,000 FU capsules a day for 2 months; groups were healthy volunteers, patients with cardiovascular risk factors and patients on dialysis; blood lipids were unaffected (Hsia et al. 2009, Nutr Res)

45 adults in Taiwan in three groups (healthy, with risk factors, or on dialysis).

Fibrinogen, factor VII and factor VIII fell over time, by 7% to 19% after 2 months, to a similar extent in all three groups; no notable adverse events were observed.

7
Nattokinase 8,000 FU and Cognition Over 6 Months (China)
PubMed

Single-center, double-blind, placebo-controlled trial (ICC-PACS, NCT05200234) of 8,000 FU a day or placebo for 6 months alongside standard treatment; 88 of 120 completed per protocol; the visuospatial result came from an exploratory analysis (Zhang et al. 2026, J Stroke Cerebrovasc Dis)

120 adults with asymptomatic narrowing of the intracranial or carotid arteries, average age 58.3 years.

No between-group difference in the change in Montreal Cognitive Assessment score (primary outcome, P = 0.948); an exploratory visuospatial score favored nattokinase (P = 0.024).

8
Single 2,000 FU Dose and Skin Temperature After Cold Water (Crossover)
PubMed

Randomized, double-blind, placebo-controlled crossover; one 2,000 FU dose of nattokinase or placebo 2 hours before a 1-minute hand immersion in 10 degree C water. Heart rate, cardiac output and sympathetic nervous activity did not differ from placebo. Supported by Japan Bio Science Laboratory, which also supplied the capsules (Nara et al. 2023, Heliyon)

9 healthy men.

Hand skin temperature recovered faster after the cold water immersion on nattokinase than on placebo (treatment interaction p < 0.05).

9
Nattokinase Alone or With Red Yeast Rice Over 6 Months (Taiwan)
PubMed

Randomized, double-blind, placebo-controlled three-arm trial: a nattokinase-only formula (50 mg per capsule), nattokinase plus red yeast rice extract, or placebo, two capsules twice daily for 6 months. The outcomes were blood lipids: after controlling for baseline, only the combined formula, not nattokinase alone, lowered total and LDL cholesterol versus placebo; funding not stated in the abstract (Yang et al. 2009, Asia Pac J Clin Nutr)

47 adults with hyperlipidemia, in three groups.

The nattokinase-only formula did not differ from placebo on the measured blood fats after controlling for baseline; only the formula combined with red yeast rice did (p<0.0001).

10
Single 2,000 FU Dose and Skin Temperature After Cold Water (Crossover)
PubMed

Randomized, double-blind, placebo-controlled crossover; one 2,000 FU dose of nattokinase or placebo 2 hours before a 1-minute hand immersion in 10 degree C water. Heart rate, cardiac output and sympathetic nervous activity did not differ from placebo. Supported by Japan Bio Science Laboratory, which also supplied the capsules (Nara et al. 2023, Heliyon)

9 healthy men.

Hand skin temperature recovered faster after the cold water immersion on nattokinase than on placebo (treatment interaction p < 0.05).

11
Nattokinase Alone or With Red Yeast Rice Over 6 Months (Taiwan)
PubMed

Randomized, double-blind, placebo-controlled three-arm trial: a nattokinase-only formula (50 mg per capsule), nattokinase plus red yeast rice extract, or placebo, two capsules twice daily for 6 months. The outcomes were blood lipids: after controlling for baseline, only the combined formula, not nattokinase alone, lowered total and LDL cholesterol versus placebo; funding not stated in the abstract (Yang et al. 2009, Asia Pac J Clin Nutr)

47 adults with hyperlipidemia, in three groups.

The nattokinase-only formula did not differ from placebo on the measured blood fats after controlling for baseline; only the formula combined with red yeast rice did (p<0.0001).

Side effects and drug interactions

Common Potential side effects

Bleeding: Memorial Sloan Kettering's About Herbs monograph says nattokinase may increase bleeding risk with blood-thinning drugs or affect lab results, and lists a case of fatal internal bleeding in an older woman who took over-the-counter nattokinase without other anticoagulants.
Clotting test changes: in an 8-week placebo-controlled trial, platelet closure time and aPTT rose more than on placebo; a single 2,000 FU dose also lengthened aPTT, within the normal range.
Brain bleed case report: a patient taking aspirin had a cerebellar hemorrhage after 7 days of nattokinase 400 mg a day; the authors linked it to the combination and existing cerebral microbleeds.
Allergy: nattokinase has been identified as an allergen (Bac s 1) in people with natto allergy, and Memorial Sloan Kettering lists severe allergic reactions in people allergic to natto. Products come from fermented soy.
Existing clots: Memorial Sloan Kettering notes that in theory nattokinase could cause an existing clot to dislodge, and says people with a history of deep vein thrombosis should avoid it.
Surgery and procedures: because nattokinase lengthened clotting test times, tell your surgeon or dentist that you take it before any procedure.

Important Drug interactions

Anticoagulants (for example warfarin, apixaban, rivaroxaban, dabigatran or heparin) and fibrinolytic drugs: Memorial Sloan Kettering advises people on anticoagulant, fibrinolytic or antithrombotic treatment to avoid nattokinase, and reports a case of a clot on a mechanical heart valve after a patient replaced warfarin with nattokinase. Do not swap or add it without your prescriber.
Aspirin and other antiplatelet drugs (for example clopidogrel): Memorial Sloan Kettering warns nattokinase may increase aspirin's effects and the risk of intracerebral hemorrhage, and a case report describes a cerebellar bleed with the combination.
Heparin: laboratory studies summarized by Memorial Sloan Kettering show nattokinase binds heparin and interferes with its interaction with antithrombin.

Frequently asked questions about Nattokinase

What is nattokinase?

Nattokinase is an enzyme made by Bacillus subtilis var. natto, the bacterium that ferments soybeans into the Japanese food natto. In laboratory tests it digests fibrin, the protein mesh that holds blood clots together. Supplements state their strength in fibrinolytic units (FU).

What is Nattokinase used for?

It is mainly taken for circulation and blood pressure support. Two 8-week placebo-controlled trials with ties to the enzyme's maker reported lower blood pressure, and a 2023 meta-analysis of six trials (546 people) pooled a 3.45/2.32 mmHg reduction. A 3-year trial in 265 healthy older adults found no effect on blood pressure, carotid wall thickening or lab measures. It is not a substitute for prescribed treatment.

What is the recommended dosage of Nattokinase?

Nattokinase is not an essential nutrient, so there is no recommended intake. Most trials used 2,000 FU a day (one trial gave 100 mg a day of the NSK-SD ingredient, standardized to at least 2,000 FU) for 8 weeks to about 3 years, and one 6-month trial used 8,000 FU a day. Follow the product label, and ask your doctor first if you take any medicine that affects clotting.

Is Nattokinase safe, and does it have side effects?

The main concern is bleeding. Nattokinase lengthened clotting test times compared with placebo, and a case report describes a brain bleed in a patient who took it with aspirin. Memorial Sloan Kettering advises people with clotting disorders or on anticoagulant, fibrinolytic or antithrombotic treatment to avoid it, and it can cause allergic reactions in people allergic to natto. Tell your doctor and surgeon if you take it.

Can nattokinase replace a prescribed blood thinner?

No. Memorial Sloan Kettering reports a case in which a patient who replaced warfarin with nattokinase after heart valve surgery developed a clot on the valve and needed a repeat valve replacement. Do not stop, swap or add to a prescribed blood thinner without your prescriber.

Does nattokinase break down spike protein?

Only in laboratory experiments. In cell studies, nattokinase degraded the SARS-CoV-2 spike protein in a dose- and time-dependent way. This was a lab study, so it does not show that taking nattokinase removes spike protein in the body.

Does Nattokinase interact with any medications?

Possible interactions include: Anticoagulants (for example warfarin, apixaban, rivaroxaban, dabigatran or heparin) and fibrinolytic drugs: Memorial Sloan Kettering advises people on anticoagulant, fibrinolytic or antithrombotic treatment to avoid nattokinase, and reports a case of a clot on a mechanical heart… If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Nattokinase?

NutraSmarts rates the evidence for Nattokinase as Limited (2 out of 5). It is backed by 11 study summaries and 18 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(18 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, Inoue K, Park S, Jang Y, Lee JH. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res. 2008;31(8):1583-8. doi: 10.1291/hypres.31.1583.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 86 adults aged 20 to 80 with untreated systolic blood pressure of 130 to 159 mmHg (pre-hypertension or stage 1 hypertension); 73 completed. Nattokinase 2,000 FU capsules for 8 weeks gave net changes versus placebo of -5.55 mmHg systolic (95% CI -10.5 to -0.57) and -2.84 mmHg diastolic (95% CI -5.33 to -0.33), both p<0.05, and a net -1.17 ng/mL/h change in plasma renin activity. Two co-authors (Ogasawara K, Inoue K) were from Japan Bio Science Laboratory Co., Ltd., a nattokinase maker (affiliations listed on the publisher page).
  2. Jensen GS, Lenninger M, Ero MP, Benson KF. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. 2016;9:95-104. doi: 10.2147/IBPC.S99553.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial (NCT02886507, primary outcome blood pressure) of 100 mg a day of NSK-SD nattokinase for 8 weeks in 79 North American adults with systolic pressure of 130 mmHg or more or diastolic pressure of 90 mmHg or more; 74 completed. Diastolic pressure fell from 87 to 84 mmHg on nattokinase and stayed at 87 mmHg on placebo (P<0.05 between groups); in men it fell from 86 to 81 mmHg (P<0.006). Systolic pressure also fell, more in men. Von Willebrand factor fell in women only at P<0.1. The full text states the study was sponsored by JBSL-USA, the distributor of the nattokinase product tested.
  3. Hodis HN, Mack WJ, Meiselman HJ, Kalra V, Liebman H, Hwang-Levine J, Dustin L, Kono N, Mert M, Wenby RB, Huesca E, Rochanda L, Li Y, Yan M, St John JA, Whitfield L. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clin Hemorheol Microcirc. 2021;78(4):339-353. doi: 10.3233/CH-211147.PubMedUsed to support: Double-blind trial (NAPS, NCT02080520, University of Southern California) in 265 adults with a median age of 65.3 years and no clinical evidence of cardiovascular disease, randomized to nattokinase 2,000 FU a day or matching placebo. After a median of 3 years, the yearly rate of change in carotid intima-media thickness and carotid arterial stiffness (primary outcomes) did not differ from placebo, and nattokinase had no significant effect on blood pressure or on any laboratory measure (metabolic, blood flow properties, clotting and fibrinolysis factors, inflammatory and cell activation markers). The authors conclude a null effect on subclinical atherosclerosis progression in healthy people at low risk. The registry (NCT02080520) lists the University of Southern California as lead sponsor with no industry collaborator; funding is not stated in the abstract.
  4. Li X, Long J, Gao Q, Pan M, Wang J, Yang F, Zhang Y. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2023;24(8):234. doi: 10.31083/j.rcm2408234.PubMedUsed to support: Systematic review and meta-analysis of six randomized controlled trials (546 participants). Versus placebo, nattokinase lowered systolic blood pressure by 3.45 mmHg and diastolic by 2.32 mmHg, slightly raised blood glucose (mean difference 0.40), and did not lower blood lipids: lower total doses were linked with higher total and LDL cholesterol and lower HDL cholesterol, higher doses with higher total cholesterol, and triglycerides did not differ. No notable adverse events were reported in the included studies. The authors report no conflict of interest.
  5. Yoo HJ, Kim M, Kim M, Lee A, Jin C, Lee SP, Kim TS, Lee SH, Lee JH. The effects of nattokinase supplementation on collagen-epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects. Food Funct. 2019;10(5):2888-2893. doi: 10.1039/c8fo02324g.PubMedUsed to support: Randomized, placebo-controlled trial (NCT02913170, Yonsei University) in 100 adults without diabetes and with serum cholesterol of 200 to 280 mg/dL (50 per group) for 8 weeks. Collagen-epinephrine closure time (a platelet function test) and activated partial thromboplastin time (aPTT) rose more on nattokinase than on placebo (P = 0.001 and P = 0.016), and prothrombin time also rose within the nattokinase group. A published correction (PMID 31287455) adds co-author Inoue K of Japan Bio Science Laboratory Co., Ltd., a nattokinase maker. The registry (NCT02913170) gives the dose as one capsule with 100 mg of nattokinase a day.
  6. Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, Hamaoka T. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 2015;5:11601. doi: 10.1038/srep11601.PubMedUsed to support: Double-blind, placebo-controlled crossover in 12 healthy young men given one 2,000 FU dose of NSK-SD nattokinase (Japan Bio Science Laboratory) or placebo. After nattokinase, D-dimer rose at 6 and 8 hours, fibrin/fibrinogen degradation products rose at 4 hours, factor VIII activity fell at 4 and 6 hours, antithrombin was higher at 2 and 4 hours and aPTT was prolonged at 2 and 4 hours (all p<0.05 or lower); all changes stayed within the normal range. Funded by a Japanese government research grant (KAKENHI), per the full text.
  7. Hsia CH, Shen MC, Lin JS, Wen YK, Hwang KL, Cham TM, Yang NC. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res. 2009;29(3):190-6. doi: 10.1016/j.nutres.2009.01.009.PubMedUsed to support: Open-label, self-controlled study with no placebo group (NCT00447434, Changhua Christian Hospital) in 45 adults: healthy volunteers, patients with cardiovascular risk factors and patients on dialysis, each taking two 2,000 FU nattokinase capsules a day for 2 months. Fibrinogen, factor VII and factor VIII declined over time, by 7% to 19% after 2 months, to a similar extent in all groups; blood lipids were unaffected and no notable adverse events were observed.
  8. Zhang K, Zhang X, Wang A, Zhong W, Pei Y, Jin H, Zhou Z, Chen C, Wang S, Lou M. Nattokinase supplementation for cognitive enhancement in asymptomatic intracranial/carotid stenosis: A randomized controlled trial. J Stroke Cerebrovasc Dis. 2026;35(1):108511. doi: 10.1016/j.jstrokecerebrovasdis.2025.108511.PubMedUsed to support: Single-center, double-blind, placebo-controlled trial (ICC-PACS, NCT05200234) in 120 patients with asymptomatic intracranial or carotid artery stenosis given nattokinase 8,000 FU a day or placebo for 6 months alongside standard treatment; 88 completed per protocol. Change in Montreal Cognitive Assessment score (primary) did not differ between groups (P = 0.948); an exploratory analysis found a between-group difference in visuospatial scores (P = 0.024). The authors report no conflicts of interest.
  9. Urano T, Ihara H, Umemura K, Suzuki Y, Oike M, Akita S, Tsukamoto Y, Suzuki I, Takada A. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem. 2001;276(27):24690-6. doi: 10.1074/jbc.M101751200.PubMedUsed to support: Laboratory study, not in people. Purified subtilisin NAT (nattokinase) cleaved plasminogen activator inhibitor 1 (PAI-1) at its reactive site and inactivated it, and enhanced tPA-induced fibrin clot lysis both without PAI-1 (attributed to direct fibrin dissolution) and more strongly with PAI-1 present.
  10. Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M. Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct. 2012;3(6):674-8. doi: 10.1039/c2fo10245e.PubMedUsed to support: Laboratory study, not in people. Nattokinase inhibited angiotensin I converting enzyme (ACE), and heat treatment that broke the enzyme into small peptides such as LY and FY increased the inhibition; the authors suggest these peptides may take part in blood pressure effects of eating natto.
  11. Chang YY, Liu JS, Lai SL, Wu HS, Lan MY. Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. Intern Med. 2008;47(5):467-9. doi: 10.2169/internalmedicine.47.0620.PubMedUsed to support: Single case report, cited for safety only: a patient taking aspirin for secondary stroke prevention had an acute cerebellar hemorrhage after taking nattokinase 400 mg a day for 7 days, with multiple cerebral microbleeds on MRI. The authors suggest nattokinase may raise the risk of brain bleeding in people with bleeding-prone small vessel disease who take another antithrombotic agent.
  12. Suzuki K, Nakamura M, Sato N, Futamura K, Matsunaga K, Yagami A. Nattokinase (Bac s 1), a subtilisin family serine protease, is a novel allergen contained in the traditional Japanese fermented food natto. Allergol Int. 2023;72(2):279-285. doi: 10.1016/j.alit.2022.11.010.PubMedUsed to support: Allergy study in 8 patients with natto allergy, cited for safety only. Nattokinase was identified as an IgE-binding allergen (named Bac s 1) in patients not sensitized to poly-gamma-glutamic acid; three such patients reacted to nattokinase on skin prick testing.
  13. Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R, Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules. 2022;27(17):5405. doi: 10.3390/molecules27175405.PubMedUsed to support: Cell and lysate study, not in people. Nattokinase degraded the SARS-CoV-2 spike protein in cell lysates in a dose- and time-dependent way and degraded spike protein on the cell surface when added to the culture medium. Three authors were from Contek Life Science Co., Ltd.; the paper declares no conflict of interest.
  14. Memorial Sloan Kettering Cancer Center. Nattokinase (About Herbs, Botanicals and Other Products). Memorial Sloan Kettering Cancer Center. 2025;Last updated May 23, 2025; accessed November 2026..SourceUsed to support: Not PubMed-indexed; hospital integrative medicine monograph, read online and cited for safety only. It states that people with coagulation disorders and those on anticoagulant, fibrinolytic or antithrombotic treatments should avoid nattokinase; that it may increase bleeding risk with blood-thinning drugs or affect lab results; that with daily aspirin it may raise the risk of intracerebral hemorrhage; and that in theory it could dislodge an existing clot, so people with a history of deep vein thrombosis should avoid it. It lists case reports of a clot on a mechanical heart valve after a patient replaced warfarin with nattokinase, fatal internal bleeding in an older woman taking over-the-counter nattokinase without other anticoagulants, and severe allergic reactions in people allergic to natto, and notes lab findings that nattokinase binds heparin.
  15. Nara N, Kurosawa Y, Fuse-Hamaoka S, Kuroiwa M, Endo T, Tanaka R, Kime R, Hamaoka T. A single dose of oral nattokinase accelerates skin temperature recovery after cold water immersion: A double-blind, placebo-controlled crossover study. Heliyon. 2023;9(7):e17951. doi: 10.1016/j.heliyon.2023.e17951.PubMedUsed to support: Double-blind, placebo-controlled crossover in 9 healthy men given one 2,000 FU dose of nattokinase or placebo 2 hours before immersing both hands in 10 degree C water for 1 minute. Hand skin temperature dropped with immersion and recovered faster after nattokinase than after placebo (treatment interaction p < 0.05); heart rate, cardiac output and sympathetic nervous activity did not differ from placebo. The study was supported by Japan Bio Science Laboratory Co., Ltd., which also provided the nattokinase and placebo.
  16. Yang NC, Chou CW, Chen CY, Hwang KL, Yang YC. Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia. Asia Pac J Clin Nutr. 2009;18(3):310-7..PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 47 patients with hyperlipidemia assigned to a nattokinase-only formula (50 mg per capsule), nattokinase combined with red yeast rice extract, or placebo, at two capsules twice daily for 6 months. After controlling for baseline levels, only the combined formula, not nattokinase alone, differed from placebo in total cholesterol, LDL cholesterol and the total/HDL cholesterol ratio; the nattokinase-only formula showed no effect on blood lipids until month six. Funding is not stated in the abstract.
  17. Nara N, Kurosawa Y, Fuse-Hamaoka S, Kuroiwa M, Endo T, Tanaka R, Kime R, Hamaoka T. A single dose of oral nattokinase accelerates skin temperature recovery after cold water immersion: A double-blind, placebo-controlled crossover study. Heliyon. 2023;9(7):e17951. doi: 10.1016/j.heliyon.2023.e17951.PubMedUsed to support: Double-blind, placebo-controlled crossover in 9 healthy men given one 2,000 FU dose of nattokinase or placebo 2 hours before immersing both hands in 10 degree C water for 1 minute. Hand skin temperature dropped with immersion and recovered faster after nattokinase than after placebo (treatment interaction p < 0.05); heart rate, cardiac output and sympathetic nervous activity did not differ from placebo. The study was supported by Japan Bio Science Laboratory Co., Ltd., which also provided the nattokinase and placebo.
  18. Yang NC, Chou CW, Chen CY, Hwang KL, Yang YC. Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia. Asia Pac J Clin Nutr. 2009;18(3):310-7..PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 47 patients with hyperlipidemia assigned to a nattokinase-only formula (50 mg per capsule), nattokinase combined with red yeast rice extract, or placebo, at two capsules twice daily for 6 months. After controlling for baseline levels, only the combined formula, not nattokinase alone, differed from placebo in total cholesterol, LDL cholesterol and the total/HDL cholesterol ratio; the nattokinase-only formula showed no effect on blood lipids until month six. Funding is not stated in the abstract.